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Abstract
Background: Recent studies have reported that cancer surgeries involving regional anesthesia have better outcomes
than those under general anesthesia. However, the effects of anesthetic technique have not been investigated in
patients with bladder cancer. Therefore, this retrospective study was conducted to investigate which anesthetic
technique results in a better bladder cancer prognosis.
Methods: Sixty-one of 531 patients underwent transurethral resection of a bladder tumor under general
anesthesia from 2001 to 2008 in our hospital. Patients who attended five years of follow-up and who had
pathological findings of urothelial carcinoma grades I–II were enrolled. Finally, 24 patients (G group) who
underwent general anesthesia and 137 (R group) who underwent regional (spinal or epidural) anesthesia were
compared. Five-year survival and recurrence-free time were compared using the chi-square and t-tests, respectively. A
logistic regression and partial correlation analysis were performed to evaluate other factors affecting survival.
Results: Five-year survival was 87.5 % for general anesthesia and 96.3 % for regional (P = 0.099). The regression analysis
showed that older age contributed to reduced survival (odds ratio = 0.85, P = 0.001). Regional anesthesia showed
higher 5-year survival (coefficient = −0.167, P = 0.044) more than general anesthesia through the partial correlation
analysis.
Conclusions: Though partial correlation analysis show that five-year survival is higher in patients whose surgery is
under regional than general anesthesia, the association was not significant in the chi-square test and logistic regression
analysis. Large prospective studies are needed to determine whether the association between regional anesthesia and
survival is causative.
Background
Cancers are frightening diseases that are difficult to cure.
Despite developments in chemotherapy and radiation
therapy, surgical tumor excision is the main treatment.
Many reports claim that anesthetic and perioperative
pain control methods alter prognosis [1–4]. Although
these results are tentative, several meta-analyses have
supported this conclusion.
Regional anesthesia decreases surgery-induced stress
and use of opioids; thus, many believe that it reduces the
likelihood of cancer recurrence [1]. No retrospective
studies are available on bladder cancer, even with its
high frequency. Transurethral resection of the bladder
tumor (TURB) is the mainstream treatment. The surgery
is usually performed under regional anesthesia, but pa-
tients who have failed regional anesthesia, have a spinal
deformity, or prefer not to be conscious undergo the op-
eration under general anesthesia. We sought to deter-
mine whether mortality due to bladder cancer differs
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between patients whose surgeries involve general versus
regional anesthesia. Therefore, this retrospective study
was conducted to investigate which anesthetic approach
results in a better bladder cancer prognosis.
Methods
This retrospective study was approved by the Chungnam
National University Hospital Institutional Review Board
and waiver of consent was passed. TURB was performed
by the same surgical and anesthesia team. Sixty-one of
531 patients underwent TURB under general anesthesia
from 2001 to 2008 at our hospital. We excluded reopera-
tions and patients who did not have five years of follow-
up. We also excluded patients with benign lesions and
those with biopsy specimen stages III and IV. Staging was
determined based on the Cecil Textbook [5]. We excluded
the case of which the cancer has grown into the layer of
fatty tissue that surrounds the bladder. The consort flow
chart is presented in Fig. 1. In the end, 24 patients under-
went general anesthesia and were compared with 137 pa-
tients who underwent regional (spinal or epidural)
anesthesia. We investigated the reasons for choosing gen-
eral anesthesia. Data were collected by three residents,
and statistics were processed by two independent
specialists.
Propofol or etomidate was used to induce general
anesthesia. Vecuronium or rocuronium was used as a
neuromuscular blocker. Isoflurane or sevoflurane was
used to maintain general anesthesia. Intravenous ketorolac
30 mg was administered for postoperative pain control at
the end of the surgery. Lidocaine and heavy bupivacaine
were used for epidural and spinal anesthesia, respectively.
The number of epidural anesthesia procedures performed
was 40, and the number of spinal anesthesia procedures
performed was 97. Regional anesthesia patients were not
treated with other analgesics for postoperative pain
control.
Radiotherapy was not conducted because we included
only types I and II. Intravesicular Bacillus Calmette-
Guerin (BCG) was administered in most cases.
Five-year survival after surgery was analyzed by chi-
square test and five-year recurrence rate and recurrence-
free time after the initial surgery were analyzed with
Kruskal-Wallis test. We used logistic regression analysis to
determine whether BCG treatment, age, sex, smoking
history, diabetes mellitus, hypertension, anesthesia type,
anesthesia time, or hospital time affected survival.
Additionally, a partial correlation analysis was performed.
SPSS version 22.0 for Windows (IBM-SPSS Inc., Chicago,




Demographic data are shown in Table 1. No differences
were observed between groups except for age and
anesthesia time. Patients who underwent general
anesthesia (67.5 ± 9.0 years) were older than those re-
ceiving regional (62.4 ± 10.8 years). Anesthesia time was
23 min longer for general than for regional anesthesia
because of emergence time. Failure of regional
anesthesia appeared to be the most common cause for
general anesthesia, followed by previous back surgery
(Table 2). No patients received a transfusion during
surgery.
Kruskal-Wallis test of recurrence and recurrence-free time
The recurrence rate in patients whose surgeries were
performed under regional anesthesia (0.9 ± 1.4) during
the five-year follow up tended to be higher than that
for patients receiving general anesthesia (0.5 ± 0.8).
Recurrence-free time was 45 ± 22 months in patients
who underwent general anesthesia during resection and
40 ± 24 months in those receiving regional anesthesia.
But recurrence rate and recurrence-free time did not
show normal distribution. Therefore Kruskal-Wallis test
was performed. Mean rank of recurrence rate was 73 in
general group and 82 in regional group (P = 0.28). Mean
Fig. 1 Flow chart of patient selection. Sixty-one patients underwent
surgery with general anesthesia. We excluded re-operations and
patients who were not followed up for five years. Patients with
benign lesions and stages III and IV on biopsy specimen reports
were also excluded
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rank of recurrence-free time 89 in general group and 80
in regional group (P = 0.33).
Finally, there are no statistical differences between two
groups about the recurrence rate and recurrence-free
time.
Chi-square test of five-year survival
Five-year survival after initial surgery (132 of 137 patients)
tended to be higher in patients who underwent regional
than general anesthesia (21 of 24 patients). Five-year
survival was 87.5 % for general anesthesia and 96.3 % for
regional. But there was neither statistical difference
(Table 3, P = 0.099) nor consideration about other factors.
Cause of death
Causes of total 8 deaths are as follows.
Regional anesthesia group had 5 deaths.
1. 75 years old male - Lung and bone metastasis
2. 73 years old male - Chronic renal failure and
ischemic cardiomyopathy
3. 65 years old male - Bone metastasis and toxic
hepatitis
4. 74 years old male - Advanced gastric cancer
5. 90 years old male - Heart failure.
General anesthesia group had 3 deaths.
1. 77 years old male - Lung and bone metastasis
2. 70 years old male - Advanced gastric cancer
3. 81 years old female - General weakness (unknown).
Logistic regression analysis for survival
Almost variables are enrolled in logistic regression ana-
lysis for survival. ENTER method was selected because
we had collected variable that could affect the survival.
Odds ratio of age was 0.847 (P = 0.005). Older age was
the main contributor to reduced five-year survival fol-
lowing surgery (Table 4).
Multivariate correlation analysis
Spearman Rho correlation analysis showed that age had a
significant correlation with survival (coefficient = −0.272,
P = 0.000) and recurrence (coefficient = 0.168, P = 0.033).
Pearson analysis showed that young patients had long
recurrence free time (coefficient = −0.172, P = 0.029).
Naturally, old patients had high ASA (coefficient = 0.216,
P = 0.006).
Table 1 Demographic data and t-test results
General (n = 24) Regional (n = 137) P value
Age (yr) 67.5 ± 9.0 62.4 ± 10.8 0.029*
Sex (M/F) 17/7 107/30 0.438
Weight (kg) 62.0 ± 9.2 62.0 ± 9.0 0.822
Height (cm) 161.2 ± 9.6 163.1 ± 7.3 0.286
Diabetes mellitus 3 20 0.788
Hypertension 7 46 0.674
ASA (I/II/III/IV) 14/6/3/1 52/75/10/0 0.634
Anesthesia time (minutes) 77.1 ± 38.2 54.1 ± 19.7 0.000*
Hospital stay (days) 9.1 ± 5.8 7.4 ± 4.6 0.110
Pathology (I/II) 14/10 56/81 0.106
Smoking history (pack year) 13.1 ± 17.7 18.4 ± 23.0 0.113
BCG treatment patients 22 114 0.375
Values are mean ± standard deviation or numbers. No significant differences were detected, except in age and anesthesia time. *P < 0.05. ASA American Society of
Anesthesiologists. BCG Bacillus Calmette-Guerin
Table 2 Reasons for general anesthesia
Reason Number
Failure of regional anesthesia 8
Previous spine operation history 6





Table 3 Comparison of five-year survival according to
anesthesia type
General Regional Total P value
Survival 21 132 153
Dead 3 5 8
Total 24 137 161 0.099
Values are numbers. No differences were observed in five-year survival accord-
ing to chi-square test
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General anesthesia has −0.145 of coefficient with survival
(P = 0.066). Patients with diabetes mellitus has −0.152 of
coefficient with survival (P = 0.055).
Female had less smoking history (coefficient = −0.156,
P = 0.049) more than male at the time of diagnosis. Stage
II patients had long hospital stay time (coefficient = 0.193,
P = 0.014). Curiously, more diabetic patients were in-
cluded in the stage II patients (coefficient = 0.179,
P = 0.023). Anesthesia time showed positive correlation
with recurrence (coefficient = 0.188, P = 0.017) and hospital
stay (coefficient = 0.363, P = 0.000). Longer anesthesia time,
recurrence free time was short (coefficient = −0.169,
P = 0.032).
Partial correlation analysis
In order to get a correct picture of the relationship be-
tween two variables, we should eliminate the influence
of other variables. So we applied the partial correlation
analysis to find a real factor influencing the 5-year sur-
vival. Table 5 showed the results. After controlling all
other factors, age had −0.186 of coefficient and 0.024 of
P value. Regional anesthesia showed higher 5-year sur-
vival (coefficient = −0.167, P = 0.044) more than general
anesthesia. Recurrence free time had 0.223 of coefficient
and 0.007 of P value. Other variables showed no signifi-
cant correlation with 5-year survival.
Discussion
Bladder cancers, which are usually transitional cell
carcinomas [6], are often multifocal and have a high
tendency to recur and progress to severe stages. Bladder
cancers are classified as superficial, muscle-invasive, or
metastatic. Superficial tumors are treated with the goal
of preventing recurrence and progression, muscle-invasive
disease is treated using surgery combined with chemo-
therapy and radiation therapy, and while metastatic
disease cannot be eradicated, it symptoms are improved
by combination chemotherapy [5]. Advances in diagnosis
and treatment over the past 30 years have increased the
five-year survival rate from 73 % (1974–1976) to 82 %
(1998–2001) [5]. Because we excluded patients with
metastases, our data show a higher five-year survival rate
(95 %).
Smoking increases the prevalence of bladder cancer
two to four times but had no impact on five-year sur-
vival or recurrence in our study. We only investigated
smoking history as self-reported by patients; thus, it may
have been inaccurately recorded. In addition, there was
no record of whether or not smoking after diagnosis of
bladder cancer.
Other risk factors are difficult to detect because the
latency of bladder cancer can be as long as 20 years.
Although cyclophosphamide also increases bladder
cancer risk up to nine times [5], we were unable to
investigate this factor here. According to multivariate
correlation analysis, more diabetic patients had been
classified the stage II than I. This result is consistent
with a recent report. Fang H et al. [7] concluded that
diabetes mellitus increases the risk of bladder cancer in
there meta-analysis study.
Surgical resection plays an important role in cancer
treatment, but cancerous cells can spread through the
Table 4 Logistic regression analysis for five-year survival
Odds ratio P value
Age (yr) 0.847 0.005*
Sex (M/F) 8.901 0.319
Weight (kg) 0.989 0.878
Height (cm) 1.065 0.590
Pathologic stage (I/II) 3.334 0.339
Anesthesia time (minutes) 1.016 0.541
Hospital stay (days) 0.875 0.152
Diabetes mellitus (no/yes) 0.128 0.129
Hypertension (no/yes) 0.343 0.392
ASA (I/II/III/IV) 0.517
Smoking (pack year) 0.967 0.092
BCG treatment (no/yes) 0.618 0.729
Anesthesia type (regional/general) 0.334 0.339
Many potential factors were evaluated by logistic regression analysis for
five-year survival. *P < 0.05. BCG Bacillus Calmette-Guerin, ASA American Society
of Anesthesiologists
Table 5 Partial correlation analysis with five-year survival
Partial correlation with survival Control variables coefficient P value
Age (yr) All other variables −0.186 0.024*
Sex (M/F) 0.057 0.491
Weight (kg) −0.008 0.922




Smoking (pack year) −0.138 0.096
Pathologic stage (I/II) 0.041 0.619
Recurrence





BCG treatment (no/yes) −0.037 0.654
Anesthesia time (minutes) 0.129 0.120
Hospital stay (days) −0.086 0.302
Diabetes mellitus (no/yes) −0.081 0.332
Hypertension (no/yes) −0.058 0.485
ASA (I/II/III/IV) −0.031 0.707
*P < 0.05. BCG Bacillus Calmette-Guerin, ASA American Society
of Anesthesiologists
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blood or lymph nodes [8]. As such cells’ viability and the
immune response to them are affected by surgery, surgi-
cal methods can affect recurrence or mortality rates.
Surgical stress, anesthetics, and opioids decrease the im-
mune response. Surgical stress appears to be a hormonal
response from the surgery itself, diminishing cell-
mediated immunity [9]. Second, anesthetics hinder the
immune response by affecting neutrophils, macrophages,
dendritic cells, T cells, and natural killer cells [10]. Third,
opioid-like agents decrease cell-mediated and humoral
immunity and increase vascularity, allowing cancer cells
to proliferate [1, 11].
Many studies have been conducted on the association
between cancer recurrence and general anesthesia. Cum-
mings et al. [1], in a large cohort study of 42,151 patients,
reported that five-year survival is higher (adjusted hazard
ratio = 0.91, P < 0.001) in patients who undergo epidural
analgesia for a colectomy. De Oliveira et al. [2] concluded
that epidural anesthesia for ovarian cancer surgery de-
creases the requirement for volatile agents and extends
recurrence-free time. Lin et al. [3] reported that epidural
anesthesia during surgery and postoperative epidural anal-
gesia decrease the mortality rate of ovarian serous adeno-
carcinoma. In that study, the general anesthesia group had
a hazard ratio of 1.214 (P = 0.043) compared with the epi-
dural anesthesia group. Our partial correlation test
showed that regional anesthesia increases 5-year survival.
However, other reports claim that regional anesthesia
or analgesia has no effect on a cancer patient’s progno-
sis. In patients with advanced ovarian cancer (stage IIIC
and IV), Lascassie et al. [12] found no benefit of epidural
anesthesia during and after tumor debulking surgery to
overall survival or time to recurrence. Roiss et al. [13]
concluded that the oncological outcomes of 4772 pa-
tients after radical prostatectomy were not affected by
adjunctive use of spinal anesthesia. In prostate cancer
patients at high risk for disease progression, general
anesthesia combined with epidural analgesia did not re-
duce the risk of cancer progression or improve survival
after retro-pubic radical prostatectomy over a median
observation time of 14 years [14]. As these studies in-
volve distinct cancers, general anesthesia may have a dif-
ferent impact depending on the tumor, perhaps in part
because of varying molecular sensitivity towards volatile
agents. Our Chi-square test and logistic regression ana-
lysis showed that anesthetic technique has no significant
impact on the survival.
We can not easily conclude that anesthesia affect the prog-
nosis of bladder cancer by combining three different analysis.
Most prior studies were conducted on patients with
terminal cancer. Because the factors affecting survival
are complex in this subgroup, we instead surveyed pa-
tients with early cancers, which likely accounts for the
strong influence of age on prognosis.
BCG is the most effective intravesical immunotherapy
for treating early-stage bladder cancer. BCG is a bacter-
ium that is related to the germ that causes tuberculosis.
BCG treatment mainly affect the cells lining the inside
of the bladder. For this reason, intravesical therapy is
used for non-invasive or minimally invasive bladder can-
cers. Because more severe patients do not receive BCG,
the treatment itself may not have impact on the progno-
sis in this study.
Conclusions from our study are limited by the small
number of cases after blocking; far fewer patients re-
ceived general than regional anesthesia. The patients
were not randomized, and clinical care was not stan-
dardized, so selection bias and the effects of unmeasured
confounding variables cannot be excluded. In addition,
though anesthesia time differed between groups, TURB
is a simple and short surgery, so this difference was
small.
Patients receiving general anesthesia were older than
those whose surgeries were performed under regional
anesthesia, probably because elderly patients are more
likely to have had spine surgery and degenerative ana-
tomical changes. A study with a larger sample size is
necessary, and results should be established through
prospective, random allocation experiments. Other cor-
relating factors, such as pain score, and postoperative in-
fection rate should be examined.
Conclusions
This is the first study to investigate the effect of
anesthetic method on the prognosis of patients with
non-metastatic bladder cancer. Though partial correl-
ation analysis show that five-year survival tends to be
higher in patients whose surgery is under regional than
general anesthesia, the association was not significant in
the chi-square test and logistic regression analysis. Ef-
fects of regional and general anesthesia on 5 year sur-
vival and cancer recurrence after transurethral resection
of the bladder tumor are not certain. We cautiously sug-
gest that there is no need to select particular anesthesia
method to achieve a better prognosis in patients with
non-metastatic bladder cancer undergoing TURB.
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